What is FUJIFILM Cellular Dynamics?
FUJIFILM Cellular Dynamics operates as a specialized biotechnology entity focused on the development and manufacturing of human iPSC-derived cells. Their portfolio encompasses a wide array of cardiac, neural, and immune cell types, which serve as essential tools for pharmaceutical organizations engaged in complex disease modeling, drug discovery, and toxicology screening. Beyond its product offerings, the company functions as a high-capacity contract development and manufacturing organization (CDMO), providing clinical-grade cellular materials that are vital for the next generation of cell-based therapies. By bridging the gap between laboratory research and clinical application, the firm provides the infrastructure necessary for precision medicine to evolve from theoretical potential to tangible patient outcomes.
How much funding has FUJIFILM Cellular Dynamics raised?
FUJIFILM Cellular Dynamics has raised a total of $161.8M across 6 funding rounds:
Private Equity
$18M
Series B
$40.6M
Private Equity
$21M
Multiple Rounds
$82.2M
Private Equity (2008): $18M, investors not publicly disclosed
Series B (2010): $40.6M, investors not publicly disclosed
Private Equity (2012): $21M, investors not publicly disclosed
Grant (2013): $16M featuring California Institute of Regenerative Medicine
Debt (2013): $20M, investors not publicly disclosed
Stock Issuance/Offering (2013): $46.2M, investors not publicly disclosed
Key Investors in FUJIFILM Cellular Dynamics
California Institute of Regenerative Medicine
A state-funded agency dedicated to accelerating the development of stem cell treatments and cures for chronic diseases and injuries.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for FUJIFILM Cellular Dynamics?
With the backing of major strategic capital, FUJIFILM Cellular Dynamics is well-positioned to accelerate its CDMO capabilities and expand its footprint in the clinical-grade cell market. The current funding context suggests a shift toward scaling manufacturing processes to meet the increasing demand for standardized, high-quality cellular inputs in therapeutic trials. Future growth will likely center on deepening partnerships with global biopharmaceutical firms and enhancing the scalability of their iPSC platforms. As the regulatory landscape for cell therapies matures, the company's ability to provide consistent, scalable, and compliant biological materials will be a primary driver of its long-term competitive advantage in the biotechnology ecosystem.
See full FUJIFILM Cellular Dynamics company page
